Company intelligence / Profile preview
Sardocor
- Ownership
- Private
- Development stage
- Phase 1
Overview
Sardocor has three ongoing FDA-approved AAV-based gene therapy clinical trials targeting HFrEF, HFpEF, and DMD-CM. SRD‑001 has received Fast Track designation from the FDA for HFpEF. The company uses a proprietary intracoronary delivery method to enhance efficacy and safety by reducing required viral titers. Interim data are positive; over a thousand doses of SRD‑001 have been manufactured. Orphan Drug Designation was granted for the DMD program. Preclinical pipeline includes additional gene therapies and small molecules.
- Therapeutic areas
- Cardiovascular
- Modalities
- Gene therapy (AAV-based)Small molecules (preclinical pipeline)
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Sardocor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sardocor.